TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 150 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $495,044 | -41.2% | 55,374 | +1.0% | 0.00% | -42.9% |
| Q2 2023 | $842,388 | -22.1% | 54,843 | +14.0% | 0.01% | -30.0% |
| Q1 2023 | $1,082,039 | +18.3% | 48,112 | +10.6% | 0.01% | +25.0% |
| Q4 2022 | $914,805 | +6.4% | 43,500 | +24.6% | 0.01% | 0.0% |
| Q3 2022 | $860,000 | -5.8% | 34,913 | -7.3% | 0.01% | -11.1% |
| Q2 2022 | $913,000 | -45.7% | 37,679 | -42.3% | 0.01% | -50.0% |
| Q1 2022 | $1,682,000 | -23.5% | 65,255 | -7.9% | 0.02% | -28.0% |
| Q4 2021 | $2,199,000 | +21.9% | 70,854 | -4.8% | 0.02% | +47.1% |
| Q3 2021 | $1,804,000 | +55.2% | 74,411 | -6.5% | 0.02% | +70.0% |
| Q2 2021 | $1,162,000 | -57.3% | 79,625 | -26.9% | 0.01% | -63.0% |
| Q1 2021 | $2,721,000 | +8.5% | 108,975 | +18.4% | 0.03% | -3.6% |
| Q4 2020 | $2,508,000 | – | 92,012 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |